Vancouver, British Columbia--(Newsfile Corp. - June 9, 2025) - EverGen Infrastructure Corp. (TSXV: EVGN), a Canadian renewable energy company specializing in waste-to-energy projects, announced today that it will be presenting at the 2025 Canadian Climate Investor Conference (CCIC), taking place on Wednesday June 11, 2025 at the Arcadian Court in Toronto, Ontario. For a complete agenda of the conference and to register, see the conference website here: https://events.tsx.com/ccic/. About EverGen Infrastruc ...

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities Laws. VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- EverGen Infrastructure Corp. (“EverGen” or the “Company”) (TSXV: EVGN) is pleased to announce that, further to its press release dated April 23, 2025, the Company has closed certain transactions contemplated under the share purchase and reorganization agreement (t ...

VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- EverGen Infrastructure Corp. (“EverGen” or the “Company”) (TSXV: EVGN) is pleased to announced that, further to its press release dated March 17, 2025, the purchase and sale agreement dated March 13, 2025 with an effective date of February 28, 2025 (the “Agreement”) between 2065947 Alberta Ltd. and James Betts (collectively, the “Purchasers”) and Fraser Valley Biogas Ltd. (the “Vendor”), a subsidiary of the Company, has received final approval fr ...

Zoom conference call scheduled for May 21, 2025, 9:00 AM ETREHOVOT, Israel, May 8, 2025 /PRNewswire/ -- May 8, 2025 - Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Wednesday, May 21, 2025.Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM I ...

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities Laws. VANCOUVER, British Columbia, April 23, 2025 (GLOBE NEWSWIRE) -- EverGen Infrastructure Corp. (“EverGen” or the “Company”) (TSXV: EVGN) is pleased to announce that it has entered into a share purchase and reorganization agreement (the “Agreement”) on April 22, 2025, with Ask America, LLC (the “Purchaser”), an arm’s length lim ...

Financial Performance and Market Conditions - The appreciation of the NIS against the U.S. dollar was (0.6%), (3.1%), and (13.2%) for the years ended December 31, 2024, 2023, and 2022, respectively, which may negatively affect financial results [154]. - The Israeli annual rate of inflation was 5.3%, 3.0%, and 3.2% for the years ended December 31, 2022, 2023, and 2024, respectively [154]. - The market price of the company's ordinary shares has declined since the reverse split, affecting total market capitalization [171]. Grants and Royalties - The company received approximately $9.4 million in royalty-bearing grants from the Israeli Innovation Authority, with a repayment of approximately $3.9 million in royalties [158]. - The company is committed to pay royalties at a rate of 3.0% - 4.0% on sales proceeds from products developed under IIA programs [157]. Nasdaq Compliance and Corporate Governance - On October 31, 2022, the company received a notification from Nasdaq for non-compliance with the minimum bid price requirement of $1.00 per share [166]. - The company was granted an additional 180-day grace period until October 30, 2023, to regain compliance with Nasdaq listing requirements [167]. - A reverse share split of 1-for-10 was executed on July 24, 2024, to temporarily regain compliance with Nasdaq listing standards [169]. - Being a public company in both the U.S. and Israel may strain resources and distract management, increasing legal and financial compliance costs [175]. - The company follows Israeli corporate governance practices instead of Nasdaq requirements, potentially providing less protection to investors [178]. - Loss of foreign private issuer status could significantly increase compliance costs and regulatory burdens [179]. Legal and Regulatory Challenges - The company may face challenges in transferring know-how and manufacturing rights outside of Israel due to restrictions from IIA grants [158]. - The company may encounter difficulties in enforcing U.S. judgments in Israel or asserting U.S. securities law claims due to its incorporation in Israel [159]. - The company currently utilizes U.S. reporting standards but may face increased compliance costs if parallel reporting obligations in Israel and the U.S. are imposed [174]. - The company incurs significant accounting, legal, and other expenses related to reporting requirements under the Exchange Act and Sarbanes-Oxley Act, which may divert management's attention from business operations [176]. - As a foreign private issuer, the company is exempt from certain U.S. regulations, which may reduce the frequency and scope of information available to investors [177]. Tax Implications - U.S. shareholders owning at least 10% of the company's ordinary shares may face adverse federal income tax consequences [180]. - The company believes it was not a Passive Foreign Investment Company (PFIC) for 2024, but there is a risk of being classified as such in 2025, which could lead to adverse tax consequences for U.S. shareholders [182]. Internal Control and Reporting - Failure to maintain effective internal control over financial reporting could adversely affect the price of the company's ordinary shares [184].

Financial Data and Key Metrics Changes - Total revenues for 2024 reached approximately $8.5 million, an increase from approximately $5.6 million in 2023, primarily driven by AgPlenus revenues from collaboration with Bayer and increased Casterra seed sales [14][56] - Q4 2024 total revenues were approximately $1.6 million, compared to $0.6 million in Q4 2023, mainly due to increased Casterra seed sales [15][56] - Total R&D expenses for 2024 were approximately $16.6 million, down from $20.8 million in 2023, with Q4 2024 R&D expenses at approximately $3.4 million, down from $5.5 million in Q4 2023 [16][57] - General and administrative expenses for 2024 increased to approximately $7.4 million from $6.1 million in 2023, influenced by one-time expenses related to fundraising [18][59] - The net loss for 2024 was approximately $18.1 million, a decrease from $26 million in 2023, with Q4 2024 net loss at approximately $5,000, down from $7.3 million in Q4 2023 [61][62] Business Line Data and Key Metrics Changes - Casterra delivered approximately 215 tons of castor seeds in 2024, with only 76 tons delivered in Q4 2024, but 250 tons delivered in February 2025 alone, indicating a resolution of previous production bottlenecks [15][20] - Lavie Bio signed a new collaboration agreement with Syngenta in February 2024 and reported advancements in biostimulants and bio fungicides throughout 2024 [23][24] - AgPlenus signed a collaboration agreement with Bayer in February 2024 and achieved milestones with Corteva for novel herbicides [25][26] Market Data and Key Metrics Changes - Casterra is focusing on expanding its seed production in Africa and Brazil, with significant demand for castor grain in both markets [21][70] - The company is exploring new commercial opportunities in the castor oil industry, leveraging its unique seed varieties and advanced growth protocols [48][49] Company Strategy and Development Direction - The company aims to position itself as a leader in life science product development, integrating advanced computational technologies with life sciences [28][30] - A targeted business strategy is in place to maximize potential while minimizing risk through collaborative partnerships for product development [32][34] - The focus for 2025 includes enhancing ChemPass AI for drug discovery and creating exit events for subsidiaries to inject funds into the company [35][36] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's potential to unlock significant value through its subsidiaries and advanced computational capabilities [11][12] - The company is committed to a capital-efficient model and anticipates achieving strategic goals in 2025 [12][34] Other Important Information - The company established an expense reduction plan expected to reduce expenses by approximately 30% by Q1 2025 [17] - The company is currently in discussions for potential collaborations and partnerships in the drug discovery space [43][46] Q&A Session Summary Question: Expected cash burn for 2025 - Expected cash burn for 2025 is projected to be between $6 million to $7 million, excluding cash from potential subsidiary sales [64] Question: Status of exit efforts for subsidiaries - Exit efforts are being prioritized, but specific details cannot be disclosed at this time [66][68] Question: Initial sales expectations in Brazil for Casterra - Initial sales in Brazil are expected to come from both seed and grain sales, with a focus on seed sales in 2025 [69][72] Question: Base case sales goal for Yalos in spring wheat and soybeans - Specific sales goals were not disclosed, but there is growing interest in Yalos for soybean growers due to higher margins [73][75] Question: Magnitude of castor sales in 2025 - Q1 2025 is expected to be a strong quarter for Casterra, with 250 tons already delivered, but not necessarily the largest quarter for the year [76][79] Question: Structure of potential joint venture for oil production - The company is currently responsible for seed production and cultivation, with plans to sell grain under offtake agreements, while not taking on responsibilities for oil production in 2025 [83][85] Question: Expense levels for 2025 - Expense levels in Q4 2024 are expected to reflect similar levels in 2025, with potential further declines anticipated [87][90]

Core Insights - Evogene Ltd. reported financial results for Q4 and full year 2024, highlighting significant revenue growth and a strategic focus on AI-powered drug discovery and subsidiary exit events [2][3][4]. Financial Performance - Total revenues for 2024 reached approximately $8.5 million, up from $5.6 million in 2023, driven by AgPlenus' collaboration with Bayer and increased seed sales from Casterra [4][11]. - Q4 2024 revenues were approximately $1.6 million, compared to $0.6 million in Q4 2023, primarily due to increased Casterra seed sales [4][11]. - R&D expenses for 2024 were approximately $16.6 million, down from $20.8 million in 2023, reflecting reduced activities in several subsidiaries [4][12]. - General and administrative expenses increased to approximately $7.4 million in 2024 from $6.1 million in 2023, influenced by one-time fundraising costs [4][16]. - The net loss for 2024 was approximately $18.1 million, a decrease from $26.0 million in 2023, attributed to higher revenues and lower R&D expenses [20]. Strategic Focus - The company plans to enhance its ChemPass AI tech-engine for drug discovery and expects to announce collaborations with biotech firms and academic institutions [3]. - Evogene aims to create exit events for its subsidiaries to inject funds into its operations, with a focus on strengthening Casterra's market position [3][5]. - The company has initiated an expense reduction plan, targeting a 30% reduction in headcount by the end of Q1 2025 [4][10]. Subsidiary Developments - Casterra Ag Ltd. is focused on large-scale castor bean farming solutions using GeneRator AI [6]. - Lavie Bio Ltd. develops microbiome-based bio-stimulants and bio-pesticides powered by MicroBoost AI [7]. - AgPlenus Ltd. specializes in sustainable crop protection products utilizing ChemPass AI [8]. - Biomica Ltd. is advancing microbiome-based therapeutics powered by MicroBoost AI [9]. Cash Position - As of December 31, 2024, Evogene held approximately $15.3 million in cash and equivalents, with cash usage in Q4 2024 at approximately $4.6 million [10][27].

Core Insights - Evogene Ltd. has appointed Mr. Nir Nimrodi as the new Chairperson of the Board, succeeding Ms. Sarit Firon, who will remain a Board member [1][2] - Mr. Nimrodi's extensive experience in scaling life sciences businesses positions him well to guide Evogene through its next growth phase [2][3] - The company aims to leverage advanced computational capabilities and AI to enhance drug discovery processes and create significant value for shareholders [3] Company Overview - Evogene Ltd. is a computational biology company focused on revolutionizing life-science product development through big data and artificial intelligence [4] - The company has established three unique tech-engines: MicroBoost AI, ChemPass AI, and GeneRator AI, each targeting different core components for product development [5] Subsidiaries and Focus Areas - Evogene operates four subsidiaries: 1. Casterra Ag Ltd. focuses on high-yield castor seed varieties for biofuel and other industries [6] 2. Lavie Bio Ltd. develops microbiome-based ag-biologicals [6] 3. AgPlenus Ltd. works on next-generation ag chemicals for sustainable crop protection [6] 4. Biomica Ltd. is advancing microbiome-based therapeutics for human disorders [6]

Company Overview - Evogene Ltd. is a computational biology company focused on revolutionizing life-science product discovery and development through big data and artificial intelligence [3][4] - The company aims to increase the probability of success while reducing development time and costs in life-science-based products [3] Financial Results Announcement - Evogene will release its financial results for the fourth quarter of 2024 on March 6, 2025 [1] - A conference call to discuss these results is scheduled for the same day at 9:00 AM Eastern Time [2] Technology and Product Development - The company has established three unique tech-engines: MicroBoost AI, ChemPass AI, and GeneRator AI, each targeting different core components: microbes, small molecules, and genetic elements respectively [4] - Evogene develops products through strategic partnerships and collaborations, leveraging its tech-engines [4] Subsidiaries - Evogene operates four subsidiaries focused on various applications of its technology: 1. Biomica Ltd. - developing microbiome-based therapeutics [5] 2. Lavie Bio Ltd. - advancing microbiome-based ag-biologicals [5] 3. AgPlenus Ltd. - developing next-generation ag chemicals for crop protection [5] 4. Casterra Ag Ltd. - marketing superior castor seed varieties for biofuel and other industries [5]